BR9916839A - Quimioterapia combinada - Google Patents

Quimioterapia combinada

Info

Publication number
BR9916839A
BR9916839A BR9916839-1A BR9916839A BR9916839A BR 9916839 A BR9916839 A BR 9916839A BR 9916839 A BR9916839 A BR 9916839A BR 9916839 A BR9916839 A BR 9916839A
Authority
BR
Brazil
Prior art keywords
combined chemotherapy
chemotherapy
paclitaxel
formulas
combined
Prior art date
Application number
BR9916839-1A
Other languages
English (en)
Inventor
Richard Carleton Gowan
Judith Sebolt-Leopold
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9916839A publication Critical patent/BR9916839A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Patente de Invenção: <B>"QUIMIOTERAPIA COMBINADA"<D>. Inibidores mitóticos tais como paclitaxel possuem uma atividade antitumor aperfeiçoada quando usados em combinação com um inibidor seletivo de MEK, especialmente um composto de fenil amina das Fórmulas (I) e (II):
BR9916839-1A 1998-12-22 1999-12-21 Quimioterapia combinada BR9916839A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10
PCT/US1999/030485 WO2000037141A1 (en) 1998-12-22 1999-12-21 Combination chemotherapy

Publications (1)

Publication Number Publication Date
BR9916839A true BR9916839A (pt) 2001-10-09

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916839-1A BR9916839A (pt) 1998-12-22 1999-12-21 Quimioterapia combinada

Country Status (31)

Country Link
EP (1) EP1140291B1 (pt)
JP (1) JP2002532570A (pt)
KR (1) KR20010099877A (pt)
CN (1) CN1333698A (pt)
AP (1) AP2001002175A0 (pt)
AT (1) ATE310567T1 (pt)
AU (1) AU2203900A (pt)
BG (1) BG105715A (pt)
BR (1) BR9916839A (pt)
CA (1) CA2352326A1 (pt)
CZ (1) CZ20012139A3 (pt)
DE (1) DE69928568T2 (pt)
EA (1) EA200100687A1 (pt)
EE (1) EE200100339A (pt)
ES (1) ES2253928T3 (pt)
GE (1) GEP20043172B (pt)
HK (1) HK1042057A1 (pt)
HR (1) HRP20010473A2 (pt)
HU (1) HUP0104844A3 (pt)
ID (1) ID30250A (pt)
IL (1) IL143939A0 (pt)
IS (1) IS5969A (pt)
MA (1) MA26768A1 (pt)
NO (1) NO20013099L (pt)
NZ (1) NZ512859A (pt)
OA (1) OA11733A (pt)
PL (1) PL348326A1 (pt)
SK (1) SK8712001A3 (pt)
TR (1) TR200101871T2 (pt)
WO (1) WO2000037141A1 (pt)
YU (1) YU45401A (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
CA2419567A1 (en) 2000-09-01 2002-03-07 George Vande Woude Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US20070073064A1 (en) * 2003-10-08 2007-03-29 Teijin Pharma Limited Method for producing aminopyrrolidine derivatives and intermediate compounds
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
KR101318012B1 (ko) * 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
KR101400905B1 (ko) 2005-11-11 2014-05-29 아에테르나 젠타리스 게엠베하 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
CN103038364A (zh) 2010-03-09 2013-04-10 达纳-法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
ES2703208T3 (es) 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU6580598A (en) * 1997-03-21 1998-10-20 Board Of Regents, The University Of Texas System (noey2) gene compositions and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
EP1140291A1 (en) 2001-10-10
ATE310567T1 (de) 2005-12-15
NO20013099D0 (no) 2001-06-21
EA200100687A1 (ru) 2001-12-24
YU45401A (sh) 2004-07-15
AP2001002175A0 (en) 2001-06-21
HK1042057A1 (zh) 2002-08-02
AU2203900A (en) 2000-07-12
BG105715A (en) 2002-04-30
WO2000037141A1 (en) 2000-06-29
CN1333698A (zh) 2002-01-30
PL348326A1 (en) 2002-05-20
TR200101871T2 (tr) 2001-10-22
CA2352326A1 (en) 2000-06-29
IS5969A (is) 2001-06-14
CZ20012139A3 (cs) 2002-01-16
ID30250A (id) 2001-11-15
MA26768A1 (fr) 2004-12-20
KR20010099877A (ko) 2001-11-09
WO2000037141A9 (en) 2000-12-07
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
EE200100339A (et) 2002-10-15
HRP20010473A2 (en) 2002-08-31
EP1140291B1 (en) 2005-11-23
IL143939A0 (en) 2002-04-21
ES2253928T3 (es) 2006-06-01
OA11733A (en) 2005-05-12
DE69928568D1 (de) 2005-12-29
NO20013099L (no) 2001-08-20
DE69928568T2 (de) 2006-07-27
NZ512859A (en) 2004-06-25
SK8712001A3 (en) 2002-02-05
JP2002532570A (ja) 2002-10-02
HUP0104844A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
BR9916839A (pt) Quimioterapia combinada
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
BR0317822A (pt) Composição fluoroquìmica
BR9908280A (pt) Inibidores de enzimas de fosfolipase
FI19992555A (fi) Antibakteerisia oksatosolidinoniaineita, joilla on tiokarbonyylifunktionaalisuus
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
UY26205A1 (es) Derivados de indoloxoacetil piperazina antiviricos
NO20006323L (no) Glykopeptid-derivater og farmasöytiske sammensetninger som inneholder disse
ATE233247T1 (de) Phtalazinonen
DE69801048D1 (de) Fungizide trifluorophenyl-triazolopyrimidine
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
CY1112551T1 (el) Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης
MY138239A (en) Nitrogen containing heterobicycles as factor xa inhibitors
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
RS53428B (en) COMPOSITIONS AND ANTI-VIRUS ACTIVITY OF SUBSTITUTED AZAINDOLOXOSCETER PIPERAZINE DERIVATIVES
IL178727A (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
UY25712A1 (es) Benzamidas sustituidas y su aplicación en medicamentos
PT920426E (pt) Novos derivados de tiazole com efeito inibidor de fosfodiesterase
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
PT1147088E (pt) 6-arilfenantridinas com actividade inibitoria da pde-iv
BR9912307A (pt) Inibidores fkbp
BR9912374A (pt) Isoquinolinas como inibidores de urocinase

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DE ACORDO COM ART. 8O DA LPI.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/335 (2006.01), A61P 35/00 (2006.01), A61K